Retinopathy of prematurity (ROP) is one of the most common causes of severe visual impairment and blindness in children worldwide. Because the blood vessels in the retina are not fully developed, ...

化学结构：Dexamethasone-d3-1是地塞米松（Dexamethasone）的氘代标记物，其中三个氢原子被氘（D，重氢）取代。 外观：通常为 白色至类白色固体，可能呈现微黄色。 质谱分析内标：这是其最核心的应用。由于其与母体化合物（地塞米松）在化学性质上几乎相同，仅 ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.

By Sneha S K March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental drug for a rare form of blood cancer ...

Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States ...

BMY reports positive phase III SUCCESSOR-2 data as mezigdomide combo improves progression-free survival in relapsed multiple myeloma, boosting CELMoD program.

Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The ...

In this week's roundup of regulatory rulings, trainer Angel Sanchez-Pinero and vet Dr. Jason Scott have been handed down bans.

Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...

Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma ...